Rachna Sadana

Rachna Sadana

Auto-generated profile, based on publicly available information

Rachna Sadana

Department of Natural Sciences, University of Houston, Downtown, Houston, Texas 77002, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MTMukund P. Tantak
Mukund P. Tantak
LKLinus Klingler
Linus Klingler
VAV. Arun
V. Arun
AKAnil Kumar
Anil Kumar
RSRachna Sadana
Rachna Sadana
DKDalip Kumar
Dalip Kumar

15 January 2016 in RSC Advances
Verified
Journal Article
Closed access
PDF file
VOVenkataramana Reddy P O
Venkataramana Reddy P O
MTMukund P. Tantak
Mukund P. Tantak
RVReyna Valdez
Reyna Valdez
RSRajnish Prakash Singh
Rajnish Prakash Singh
OSOkram Mukherjee Singh
Okram Mukherjee Singh
DKDalip Kumar
Dalip Kumar
A new library of 24 carbazolyl glyoxamides 14a–x were designed and synthesized from glyoxalic acids and arylamines in the presence of HATU as a coupling reagent under MW irradiation. The synthesized carbazolyl glyoxamides were evaluated for their in vitro anticancer and antibacterial activities. Of the synthesized carbazolyl glyoxamides, compounds 14l and 14q exhibited the most potent cytotoxicity towards a breast cancer cell line with IC50 values of 9.3 and 9.8 μM, respectively. Further, caspase-3 assay for carbazolyl glyoxamides indicated that these compounds induced apoptotic cell death in Jurkat cells. Furthermore, some of the synthesized carbazolyl glyoxamides 14g, 14k, 14l and 14n exhibited comparable or even better antibacterial activity (MIC = 8–16 μg mL−1) than chloramphenicol against the selected bacterial strains.

1 April 2021 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MTMukund P. Tantak
Mukund P. Tantak
MMMonika Malik
Monika Malik
LKLinus Klingler
Linus Klingler
ZOZachary Olson
Zachary Olson
AKAnil Kumar
Anil Kumar
DKDalip Kumar
Dalip Kumar

3 September 2024 in ACS Omega
Verified
Journal Article
Open access
RARanjana Aggarwal
Ranjana Aggarwal
PKPrince Kumar
Prince Kumar
SKSuresh Kumar
Suresh Kumar
RSRachna Sadana
Rachna Sadana
RLRobert Lwanga
Robert Lwanga
VCVaishali Chaubal
Vaishali Chaubal
Cancer, defined by uncontrolled cell growth, poses a significant global health challenge, necessitating the development of new anticancer drugs crucial to address drug resistance, side effects, and the need for combination therapies. The study presents the design, synthesis, and anticancer screening of a series of novel functionalized arylidene-hydrazinyl-thiazoles against various human cancer cell lines. The environmentally benign synthetic protocol involves the visible-light prompted, NBS-mediated domino reaction of thiosemicarbazide, heteroaryl aldehydes, and unsymmetrical 1,3-diketones. The regioselective organic transformation delivered the single regioisomeric product, characterized unambiguously through detailed 2D NMR spectral studies. In vitro cytotoxic studies revealed that the synthesized derivatives exhibited excellent cytotoxic potential against BxPC-3, MOLT-4, and MCF-7 cancer cell lines. Notably, compounds 4m, 4n, and 4r showed significant cytotoxicity, reducing cell survival to 23.85-26.45% for BxPC-3, 30.08-33.30% for MOLT-4, and 44.40-47.63% for MCF-7 at a concentration of 10 μM. These compounds profoundly induced apoptosis, evidenced by increased caspase-3/7 activity, loss of mitochondrial membrane potential, and modulation of Bcl2 and Bax gene expression. Additionally, these compounds caused robust cell cycle arrest at the G2/M phase by inhibiting tubulin polymerization, indicating their multifaceted impact on cancer cells.